ENTA - NASDAQ
Enanta Pharmaceuticals, Inc.
$11.90
-1.1%Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotEnanta Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Enanta Pharmaceuticals, Inc. Cash Flow Statement
ENTA • NASDAQ
| Enanta Pharmaceuticals, Inc. Cash Flow Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||
-81.9M | -116M | -133.8M | -121.8M | -79M | -36.2M | 46.4M | 72M | 17.7M | 21.7M | 79M | 34.4M | 9.6M | 21.4M | 23.3M | 7.9M | |
5.1M | 2.3M | 2.4M | 3M | 3.3M | 3.6M | 3.3M | 2.5M | 2.1M | 1.7M | 639K | 352K | 221K | 172K | 499K | 553K | |
0.0 | 0.0 | 0.0 | 0.0 | 345K | 10.6M | -3.1M | 1.9M | -1.7M | -2.3M | 11M | -15.2M | 781K | 0.0 | -360K | 0.0 | |
18.6M | 26.8M | 28.2M | 27M | 21M | 19.6M | 19.2M | 15.8M | 13.1M | 9.4M | 5.8M | 2.7M | 1.1M | 424K | 225K | 259K | |
-946K | 1M | -7.9M | 242K | -2M | -3.5M | -5.8M | -1.2M | -581K | -749K | -3M | 176K | -1.8M | 535K | 2.7M | -480K | |
(109K) | (241K) | (4.9M) | (0.0) | (32K) | (105K) | (12.7M) | (26.1M) | (1.6M) | (12.6M) | (40.1M) | (148K) | (0.0) | (0.0) | (0.0) | (157K) | |
39.9M | 7.1M | 8M | 6.8M | -13.7M | 12.9M | 11.5M | -61.8M | 22M | 6.2M | -16.8M | -2.3M | 741K | 93K | -2.4M | -18.4M | |
-19.3M | -78.8M | -103.2M | -84.8M | -70M | 7.1M | 71.4M | 29.2M | 52.7M | 35.8M | 76.7M | 20.2M | 10.7M | 22.6M | 24M | -10.2M | |
INVESTING ACTIVITIES | ||||||||||||||||
-12.9M | -17.9M | -9.1M | -2.1M | -750K | -1.4M | -5.4M | -3M | -2.5M | -4.7M | -2.3M | -1M | -606K | -252K | -445K | -37K | |
(0.0) | (0.0) | (44.5M) | -54.9M | -37.7M | (0.0) | (86.7M) | (0.0) | (0.0) | (0.0) | (9K) | (0.0) | (0.0) | (66K) | (9K) | (0.0) | |
-209.6M | -307.3M | -373.4M | -171.4M | -307.3M | -338.6M | -549.3M | -293.1M | -251.4M | -192.4M | -196.3M | -98.4M | -115.9M | -47.7M | -33.6M | -603K | |
262.9M | 383.5M | 328.9M | 228.5M | 345.1M | 359.8M | 468.1M | 260.7M | 249.3M | 153.5M | 110.6M | 99.9M | 47.3M | 28.7M | 16.8M | 2.3M | |
0.0 | 0.0 | -44.5M | 54.9M | 37.7M | 0.0 | -86.7M | -32.4M | -2.1M | -38.9M | -172K | 3K | -68.6M | 1.1M | -436K | 0.0 | |
(40.3M) | (58.2M) | -53.6M | (54.9M) | (37M) | (19.8M) | -86.7M | -35.4M | -4.6M | -43.7M | -88.2M | (497K) | -69.2M | -18M | -17.7M | (1.7M) | |
FINANCING ACTIVITIES | ||||||||||||||||
145K | 147K | 2.2M | 21.3M | 3.6M | 10.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 59.9M | 0.0 | 0.0 | 0.0 | |
-26.5M | -27.5M | 199.7M | 0.0 | 0.0 | 0.0 | -86K | -79K | -73K | -68K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4.2M | -1.8M | -202K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-277K | -294K | -3.8M | -1.2M | -534K | -1.5M | 2.7M | 4.5M | 1.1M | 2.8M | 2.5M | 1.2M | -3M | -909K | 34K | 15K | |
-26.6M | -27.6M | 198.1M | 20M | 3.1M | 9M | 2.6M | 4.4M | 1M | 2.7M | 2.5M | 1.2M | 56.9M | -909K | 34K | 8K | |
CASH FLOW SUMMARY | ||||||||||||||||
-5.5M | -48.2M | 41.4M | -9.9M | -29.9M | 35.9M | -12.7M | -1.8M | 49.1M | -5.1M | -9M | 21.8M | -1.7M | 3.7M | 6.4M | -8.5M | |
41.2M | 89.4M | 48M | 57.8M | 87.7M | 51.8M | 64.5M | 65.7M | 16.6M | 21.7M | 30.7M | 8.9M | 10.5M | 6.8M | 466K | 9M | |
35.7M | 41.2M | 89.4M | 48M | 57.8M | 87.7M | 51.8M | 63.9M | 65.7M | 16.6M | 21.7M | 30.7M | 8.9M | 10.5M | 6.8M | 466K | |
-32.2M | -96.7M | -112.2M | -86.9M | -70.7M | 5.6M | 66M | 26.2M | 50.1M | 31.1M | 74.3M | 19.2M | 10M | 22.4M | 23.6M | -10.2M |
SEC Filings
ENTA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 11, 2026 | 2026 | |
S-3 S-3 N/A | February 11, 2026 | February 11, 2026 | ||
10-Q 10-Q 2025 Q4 Q4 | February 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 09, 2026 | February 09, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | March 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | November 19, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 |
Related Guides
Continue your ENTA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.